JP2002508656A - 抗−アルファベータ3ヒト化モノクローナル抗体 - Google Patents
抗−アルファベータ3ヒト化モノクローナル抗体Info
- Publication number
- JP2002508656A JP2002508656A JP53986098A JP53986098A JP2002508656A JP 2002508656 A JP2002508656 A JP 2002508656A JP 53986098 A JP53986098 A JP 53986098A JP 53986098 A JP53986098 A JP 53986098A JP 2002508656 A JP2002508656 A JP 2002508656A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- human
- seq
- antibodies
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.配列番号4および5の少なくとも1つのCDR配列を含有する重鎖を含む 、ヒトαvβ3タンパク質受容体と特異的に反応し、該受容体を中和する能力を有 する改変抗体およびその抗体の機能的フラグメント。 2.配列番号9および10の少なくとも1つの軽鎖CDR配列を含有する軽鎖 を有する請求項1記載の抗体。 3.重鎖が配列番号4および5の3つのCDRを含有する請求項1記載の抗体 。 4.軽鎖が配列番号9および10の3つのCDRを含有する請求項3記載の抗 体。 5.配列番号10の軽鎖アミノ酸配列および配列番号5の重鎖アミノ酸配列を 含有する請求項1記載の抗体。 6.配列番号15の軽鎖アミノ酸配列および配列番号5の重鎖アミノ酸配列を 含有する請求項1記載の抗体。 7.配列番号5の重鎖アミノ酸配列およびヒト抗体の軽鎖を含有する請求項1 記載の抗体。 8.フラグメントがFv、FabおよびF(ab')2からなる群から選択される 請求項1記載の抗体。 9. (a)請求項1−8のいずれか1項記載の抗体およびフラグメントのい ずれかをコードする核酸配列; (b)(a)の配列のいずれかと相補的な核酸;および (c)ストリンジェント条件下、(a)または(b)にハイブリダイズする能 力を有する18またはそれ以上のヌクレオチドからなる核酸配列 からなる群から選択される単離核酸分子。 10.請求項9の核酸配列を含有する組換えプラスミド。 11.請求項10のプラスミドを含有する宿主細胞。 12.時間、温度およびpHの適当な条件下、培地中で請求項11記載の宿主 細胞を培養し、そうして生産された抗体を回収することを特徴とする、ヒトαv β3受容体に対して特異的なヒト抗体の生産方法。 13.過剰発現したヒトαvβ3受容体を含有すると思われる源を請求項1記載 の抗体の診断上有効量と接触させ、抗体の該源への結合を測定することを特徴と する、ヒトαvβ3受容体の過剰発現により特徴付けられる障害の検出方法。 14.医薬上許容される担体中、請求項1記載の抗体の免疫療法上有効量を少 なくとも1回用量含有する医薬組成物。 15.少なくとも1つの別のモノクローナル抗体と組み合わせて、請求項1記 載の抗体の免疫療法上有効量を少なくとも1回用量含有する医薬組成物。 16.別のモノクローナル抗体が、ヒトαvβ3タンパク質の異なるエピトープ と反応することにより請求項1記載の抗体とは異なるヒトαvβ3抗体である請求 項15記載の医薬組成物。 17.ヒトαvβ3受容体と特異的に反応し、該受容体を中和し、配列番号1お よび2の少なくとも1つのCDR配列を含有する重鎖を有することを特徴とする 、ネズミモノクローナル抗体およびその機能的フラグメント。 18.配列番号6または7の少なくとも1つの軽鎖CDR配列を含有する軽鎖 を有する請求項17記載の抗体。 19.重鎖が配列番号1または2の3つのCDRを含有する請求項17記載の 抗体。 20.軽鎖が配列番号6または7の3つのCDRを含有する請求項17記載の 抗体。 21.配列番号7の軽鎖アミノ酸配列および配列番号2の重鎖アミノ酸配列を 含有する請求項17記載のモノクローナル抗体。 22.フラグメントがFv、FabおよびF(ab')2からなる群から選択され る請求項17記載のモノクローナル抗体。 23.請求項1記載の抗体の免疫療法上有効量をヒトに投与することからなる ことを特徴とする、ヒトにおいてビトロネクチン受容体により媒介される疾患に 受動免疫療法を与える方法。 24.受動免疫療法が予防的に与えられる請求項23記載の方法。 25.疾患が再狭窄である請求項23記載の方法。 26.疾患が脈管形成関連疾患である請求項23記載の方法。 27.疾患が、癌転移、慢性関節リウマチ、アテローム性動脈硬化症、糖尿病 性網膜症および黄斑変性からなる群から選択される請求項26記載の方法。 28.ヒトにおいてビトロネクチン受容体により媒介される疾患に受動免疫療 法を与えるための薬物の製造における請求項1記載の抗体の使用。 29.請求項1記載の抗体の免疫療法上有効量をヒトに投与し、該受容体のア ンタゴニストである小型化学分子の治療上有効量をかかるヒトに投与することか らなることを特徴とする、ヒトにおけるビトロネクチン受容体により媒介される 疾患の治療方法。 30.抗体が小型分子の投与前にヒトに投与される請求項29記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3960997P | 1997-03-12 | 1997-03-12 | |
US60/039,609 | 1997-03-12 | ||
PCT/US1998/004987 WO1998040488A1 (en) | 1997-03-12 | 1998-03-12 | Anti-alphabeta3 humanized monoclonal antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002508656A true JP2002508656A (ja) | 2002-03-19 |
JP2002508656A5 JP2002508656A5 (ja) | 2005-11-10 |
Family
ID=21906403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53986098A Pending JP2002508656A (ja) | 1997-03-12 | 1998-03-12 | 抗−アルファベータ3ヒト化モノクローナル抗体 |
Country Status (8)
Country | Link |
---|---|
US (3) | US7230083B2 (ja) |
EP (2) | EP1491632A3 (ja) |
JP (1) | JP2002508656A (ja) |
AU (1) | AU6702998A (ja) |
CA (1) | CA2284518A1 (ja) |
DE (1) | DE69828154T2 (ja) |
ES (1) | ES2234099T3 (ja) |
WO (1) | WO1998040488A1 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1491632A3 (en) * | 1997-03-12 | 2006-01-04 | Smithkline Beecham Corporation | Anti-alphavbeta3 humanized monoclonal antibodies |
GB9823071D0 (en) * | 1998-10-21 | 1998-12-16 | Affibody Technology Ab | A method |
US6160099A (en) * | 1998-11-24 | 2000-12-12 | Jonak; Zdenka Ludmila | Anti-human αv β3 and αv β5 antibodies |
US7906102B2 (en) | 2001-10-03 | 2011-03-15 | Vanderbilt University | Ligands to radiation-induced molecules |
US7306925B2 (en) | 2001-11-09 | 2007-12-11 | Vanderbilt University | Phage antibodies to radiation-inducible neoantigens |
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
US7674884B2 (en) * | 2003-12-10 | 2010-03-09 | Novimmune S.A. | Neutralizing antibodies and methods of use thereof |
US7351739B2 (en) | 2004-04-30 | 2008-04-01 | Wellgen, Inc. | Bioactive compounds and methods of uses thereof |
DE102004059357B8 (de) * | 2004-12-03 | 2009-12-03 | Universität Leipzig | Antikörper, welcher die Interaktion von humanem Thy-1 und dessen Liganden blockiert, sowie dessen Verwendung |
EP1907001B1 (en) | 2005-06-17 | 2015-07-15 | Merck Sharp & Dohme Corp. | Ilt3 binding molecules and uses therefor |
US7777008B2 (en) | 2006-06-19 | 2010-08-17 | Tolerx, Inc. | ILT3 binding molecules and uses therefor |
WO2008008373A2 (en) | 2006-07-11 | 2008-01-17 | Arubor Corp | Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors |
CA3177366A1 (en) | 2006-08-10 | 2008-02-21 | Roy C. Levitt | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
WO2010002862A2 (en) * | 2008-07-01 | 2010-01-07 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (fgfr3) binding proteins |
WO2013019730A1 (en) * | 2011-07-29 | 2013-02-07 | The Washington University | Antibodies to tip-1 and grp78 |
EP3172222A4 (en) | 2014-07-24 | 2018-03-21 | Washington University | Compositions targeting radiation-induced molecules and methods of use thereof |
WO2018148595A1 (en) | 2017-02-10 | 2018-08-16 | Washington University | Antibodies to tip1 and methods of use thereof |
CA3172092A1 (en) * | 2020-04-23 | 2021-10-28 | David Cheresh | Compositions and methods for treating cancer |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989005155A1 (en) * | 1987-11-19 | 1989-06-15 | Scripps Clinic And Research Foundation | Monoclonal antibody against the rgd-directed adhesion receptor of endothelial cells |
ATE175241T1 (de) * | 1992-04-03 | 1999-01-15 | Genentech Inc | Antikörper gegen alpha v beta 3 integrin |
WO1995024400A1 (en) * | 1994-03-08 | 1995-09-14 | American Home Products Corporation | Thiazolidinedione derivatives as anti-hyperglycemic agents |
US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
EP1491632A3 (en) * | 1997-03-12 | 2006-01-04 | Smithkline Beecham Corporation | Anti-alphavbeta3 humanized monoclonal antibodies |
US6160099A (en) * | 1998-11-24 | 2000-12-12 | Jonak; Zdenka Ludmila | Anti-human αv β3 and αv β5 antibodies |
-
1998
- 1998-03-12 EP EP04077315A patent/EP1491632A3/en not_active Withdrawn
- 1998-03-12 AU AU67029/98A patent/AU6702998A/en not_active Abandoned
- 1998-03-12 EP EP98909183A patent/EP0968290B1/en not_active Expired - Lifetime
- 1998-03-12 JP JP53986098A patent/JP2002508656A/ja active Pending
- 1998-03-12 CA CA002284518A patent/CA2284518A1/en not_active Abandoned
- 1998-03-12 DE DE69828154T patent/DE69828154T2/de not_active Expired - Fee Related
- 1998-03-12 WO PCT/US1998/004987 patent/WO1998040488A1/en active IP Right Grant
- 1998-03-12 ES ES98909183T patent/ES2234099T3/es not_active Expired - Lifetime
-
2002
- 2002-08-20 US US10/223,880 patent/US7230083B2/en not_active Expired - Fee Related
-
2006
- 2006-10-18 US US11/582,745 patent/US7504102B2/en not_active Expired - Fee Related
-
2007
- 2007-04-25 US US11/739,755 patent/US20080160576A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE69828154T2 (de) | 2005-06-23 |
ES2234099T3 (es) | 2005-06-16 |
US7504102B2 (en) | 2009-03-17 |
EP0968290B1 (en) | 2004-12-15 |
EP1491632A3 (en) | 2006-01-04 |
DE69828154D1 (de) | 2005-01-20 |
EP0968290A1 (en) | 2000-01-05 |
US7230083B2 (en) | 2007-06-12 |
AU6702998A (en) | 1998-09-29 |
WO1998040488A1 (en) | 1998-09-17 |
CA2284518A1 (en) | 1998-09-17 |
US20030152571A1 (en) | 2003-08-14 |
US20080160576A1 (en) | 2008-07-03 |
EP1491632A2 (en) | 2004-12-29 |
US20070053902A1 (en) | 2007-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7504102B2 (en) | Anti-αvβ3 humanized monoclonal antibodies | |
EP1135477B1 (en) | Humanized monoclonal integrin antibodies | |
US7422744B2 (en) | Methods of treating cancer with alphavbeta3-specific antibodies | |
JP4521802B2 (ja) | 抗αvβ3組換えヒト抗体、これをコードする核酸およびその使用方法 | |
AU2001283903B2 (en) | Antibodies to human MCP-1 | |
US20110250165A1 (en) | Antibodies against CXCR4 and Methods of Use Thereof | |
JPH09512705A (ja) | E−セレクチンに対する抗体 | |
JP2002542769A (ja) | Il−18により媒介される疾病の治療において有用な組み換えil−18アンタゴニスト | |
JP2007530551A (ja) | 抗ミオスタチン抗体 | |
US20020127227A1 (en) | RHAMM antagonist antibodies | |
WO1998040488A9 (en) | Anti-alphabeta3 humanized monoclonal antibodies | |
US6777540B1 (en) | Humanized immunoglobulin reacting specifically with Fas ligand or active fragments thereof and region inducing apoptosis originating in Fas ligand | |
JP2001523083A (ja) | Il−5により媒介される疾病の治療に有用な組み換えil−5アンタゴニスト | |
US20230138315A1 (en) | Anti-angptl3 antibody and use thereof | |
EP3412688A1 (en) | Thrombin antibody, antigen-binding fragment and pharmaceutical use thereof | |
JP6469644B2 (ja) | 抗ccr7抗原結合タンパク質に関係する方法および組成物 | |
JP4860877B2 (ja) | シアロアドへジンファクター−2抗体 | |
CA3152860A1 (en) | Anti-tfpi monoclonal antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050225 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050225 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071120 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080220 |
|
A524 | Written submission of copy of amendment under section 19 (pct) |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20080220 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090317 |